Up-and-over access is not an optimal pathway for percutaneous catheter-directed thrombolysis in acute iliofemoral popliteal venous thrombosis

• Published in: Vascular Vol. 31; no. 4; p. 807
• Main Authors: Li, Fandong, Tang, Dianjun, Guo, Yanan, Yang, Yanfei, Wang, Fengchun, Wu, Mengtao
• Format: Journal Article
• Language: English
• Published: England 01.08.2023
• Subjects: access; catheter-directed thrombolysis; venous, thrombosis; popliteal; Up-and-over
• ISSN: 1708-539X
• DOI: 10.1177/17085381221087061

To analyze the feasibility and results of up-and-over access (UOA) for catheter-directed thrombolysis (CDT) in acute iliofemoral popliteal venous thrombosis (IFPVT). From June 2020 to June 2021, a total of 26 patients (26 lower limbs) undergoing CDT for IFPVT were included. According to the vascular access, the patients were divided into UOA group ( = 11, 10 left limbs and 1 right limb) and ipsilateral popliteal vein (ILPV) ( = 15, 15 left limbs) access group. The differences in preoperative characteristics and technical details between the two groups were compared. Patients in UOA group were older than those in ILPV access group (67.64 ± 4.11 years VS. 52.73 ± 15.63 years, = .003). The BMI of UOA group was significantly higher than that of ILPV access group (26.03 ± 1.62 kg/m VS 24.71 ± 1.46 kg/m , = .039). There were significantly more patients with simultaneous three comorbidities in UOA group than in ILPV access group (45.5% vs. 0, = .043). Compared with ILPV access group, the duration of operation and fluoroscopy of UOA group were significantly longer (20.64 ± 3.41 min vs. 10.20 ± 1.42 min, < .001; 18.18 ± 2.99 min vs. 6.13 ± 0.92 min, < .001), but the technical success rate was significantly lower (54.5% vs. 100%, = .007). In UOA group, the operation-related complications occurred, including catheter straying into lateral sacral vein (9.1%), retroperitoneal hematoma (9.1%), and thrombus shedding into filter (9.1%). The UOA may be attempted in patients who are unable to be prone, but this access is not an optimal pathway for CDT.